Biocryst Pharmaceuticals — Q2 2022 Earnings Presentation

5 slides from Biocryst Pharmaceuticals's earnings presentation, Aug 4, 2022

Slide 1: Second Quarter 2022 Results Call
Second Quarter 2022 Results Call Corporate Update & Financial Results August 4, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Officer ◆ Financial Update Anthony Doyle – Chief Financial Officer ◆ BCX9930 Update Dr. Helen Thackray – Chief Research and Development Officer
Slide 4: Finance Summary
Finance Summary (figures in millions) 2Q22 Cash Position Cash, cash equivalents, restricted cash & investments at June 30, 2021 $223 Cash, cash equivalents, restricted cash & investments at June 30, 2022 $419 Senior Credit Facility A $151 Proforma cash, cash equivalents, restricted cash & investment
Slide 5: Second Quarter 2022 Results Call
Second Quarter 2022 Results Call Corporate Update & Financial Results August 4, 2022